Relevant bibliographies by topics / Transcutol P

Contents

  1. Journal articles

Academic literature on the topic 'Transcutol P'

Author: Grafiati
Published: 4 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Transcutol P.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Transcutol P"

1

Kuncahyo, Ilham, Shabrina Nindya Hutami, and RR Sri Wulandari. "PENGARUH TRANSCUTOL P DAN PEG 400 DALAM PEMBUATAN TABLET LIQUISOLID NIFEDIPIN TERHADAP MUTU FISIK DAN DISOLUSI." Cendekia Journal of Pharmacy 9, no. 1 (2025): 60–68. https://doi.org/10.31596/cjp.v9i1.330.

Full text
Abstract:
Nifedipine as a hypertension drug has the problem of low solubility (BCS class II), leading to decreased dissolution and bioavailability. Formulation of nifedipine liquisolid using non-volatile solvents can overcome this problem. This study aimed to evaluate the effect of Transcutol P and PEG 400 as non-volatile liquisolid ingredients on the physical quality and dissolution of nifedipine liquisolid tablets. This study used seven nifedipine liquisolid formulations, each with varying concentrations of Transcutol P or PEG 400 as non-volatile solvents and lactose as carrier material. Formula 1 (20% Transcutol: 80% lactose), Formula 2 (25% Transcutol: 75% lactose), Formula 3 (30% Transcutol: 70% lactose), Formula 4 (20% PEG 400: 80% lactose), Formula 5 (25% PEG 400: 75% lactose), Formula 6 (30% PEG 400: 70% lactose), and one control formula. The nifedipine liquid produced from each formula was forged into tablets using the direct felting method with a weight of approximately 200 mg. The tablets were tested for physical quality and dissolution, and the results were statistically analyzed using SPSS version 12.0. The results showed that Transcutol P and PEG 400 as liquisolid ingredients for nifedipine tablets provided good physical quality and improved the quantity and rate of drug release. The effect of PEG 400 as a liquisolid material for nifedipine tablets slowed down the disintegration time and accelerated the dissolution rate compared with Transcutol P. The dissolution profile showed that the release of nifedipine tablets with PEG 400 liquisolid material reached 30% at the fifth minute, meeting the requirements according to Indonesian Pharmacopoeia VI, which stipulates that more than 75% should be released at the sixtieth minute
APA, Harvard, Vancouver, ISO, and other styles
2

Hashemzadeh, Nastaran, and Abolghasem Jouyban. "Review of Pharmaceutical Applications of Diethylene Glycol Monoethyl Ether." Journal of Pharmacy & Pharmaceutical Sciences 25 (November 6, 2022): 340–53. http://dx.doi.org/10.18433/jpps32921.

Full text
Abstract:
Diethylene glycol monoethyl ether (DEGME) is a hydroalcoholic solvent that gained tremendous attention in the cosmetics, food, nanoformulations, and pharmaceutical industries. Due to its physicochemical features, it has been widely used as a penetration enhancer, surfactant, and solubilizer. Among numerous tradenames defined for DEGME -- Carbitol® (by Dow Chemical Co., USA), and Transcutol® HP, CG, and P. (by Gattefossé Co., France) -- are known to be employed in pharmaceutical industries. Transcutol® CG is utilized only in cosmetics; however, Transcutol® P and Carbitol® are both used in various pharmaceutical topical dosage forms such as creams, gels, etc. Additionally, Transcutol® HP is used in all administration routes. In view of this, the application of DEGME is highlighted in the areas of industry and pharmaceutical sciences. Moreover, in this review the prominent characteristics, pharmacokinetics, and toxicity of DEGME are examined and it is suggested that DEGME is a promising solvent/solubilizer with comparable assignments to other conventional excipients.
APA, Harvard, Vancouver, ISO, and other styles
3

Ojo, Olusola Emmanuel, Margaret Okonawan Ilomuanya, Ibilola Mary Cardoso-Daodu, et al. "Mupirocin/hydroxyapatite composite suspended in transcutol P-spiked hydrogel: In vitro characterization and in vivo wound healing assessment." American Journal of Pharmacotherapy and Pharmaceutical Sciences 3 (June 3, 2024): 11. http://dx.doi.org/10.25259/ajpps_2024_011.

Full text
Abstract:
Objectives: Natural hydroxyapatite (HAP) has been utilized as a drug carrier owing to its excellent bioactivity and biocompatibility. This study is aimed at formulating mupirocin/hydroxyapatite composite suspended in hydrogel. The appropriate quantity of the penetration enhancer (Transcutol-P®) was also investigated. Materials and Methods: The HAP was isolated from bovine bone by hydrothermal treatment, calcined at 1000oC and held for 2 hours in an electric furnace to remove the organic contents. The bones were milled, sifted using 150 µm mesh sieve and characterized. Olive oil, which contains oleic acid, was utilized as a natural capping agent to prevent agglomeration of the particles in the formulation. The quantity of Transcutol-P® was varied with mupirocin used as the active pharmaceutical ingredient for the management of acute wound in Wistar rats. In this animal study, the wound closure rate was evaluated. Results: The formulation with the 0.6%v/v, of Transcutol-P® gave the best wound closure rate of 30.05 mm2/day. The in-vitro study showed that the formulation containing 0.6%v/v Transcutol-P® released 63.9% of the drug after 75 minutes while 42.4% was released at the same time interval when the concentration of the penetration enhancer was increased to 1.2%v/v. The mupirocin-encapsulated HAP hydrogel composite showed high resistance against staphylococcus saprophyticus with inhibition zone of 37.3 mm. Conclusion: The mupirocin encapsulated in HAP allows for sustained release of the antibiotic and thus serves as a veritable drug carrier suitable for wound healing applications. Transcutol-P® (0.6%v/v) is effective in facilitating drug release, which is reflected in the increased wound closure rate in Wistar rats.
APA, Harvard, Vancouver, ISO, and other styles
4

Date, Abhijit A., and Mangal S. Nagarsenker. "Single-step and low-energy method to prepare solid lipid nanoparticles and nanostructured lipid carriers using biocompatible solvents." European Journal of Pharmaceutical Research 1, no. 1 (2019): 12–19. http://dx.doi.org/10.34154/2019-ejpr.01(01).pp-12-19/euraass.

Full text
Abstract:
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) are widely being explored for improving dermal/transdermal and oral delivery of drugs, neutraceuticals and cosmeceuticals. High-pressure homogenization (HPH) is the most commonly used preparation method for SLN/NLCs. SLN/NLCs preparation by the HPH requires high energy input and longer duration. Here, we describe a simple yet innovative low-energy method to prepare SLN/NLCs in a single-step using biocompatible solvents. We first show that biocompatible solvents such as Transcutol P, Soluphor P, N-methyl pyrrolidone, and glycofurol can solubilize glyceryl monostearate, glyceryl behenate, and glyceryl distearate to a variable degree. Our pre-formulation studies showed that only GMS could be transformed into SLN or NLCs despite high solubility of the lipids investigated indicating the importance of solvent-lipid interaction parameter in our preparation method. Finally, we show that SLN and NLCs of glyceryl monostearate with size < 150 nm and acceptable polydispersity index can be easily developed using Transcutol P as a biocompatible solvent and polyoxyl-40-stearate (MYS-40) as a stabilizer. As the Transcutol P has excellent acceptability for dermal/transdermal and oral route, there is no need to remove the residual Transcutol P (5% v/v) from the prepared glyceryl monostearate SLN/NLCs. Thus, our method offers a simple yet innovative way to prepare GMS SLN/NLCs suitable for dermal/transdermal and oral applications.
APA, Harvard, Vancouver, ISO, and other styles
5

Pitzanti, Giulia, Antonella Rosa, Mariella Nieddu, et al. "Transcutol® P Containing SLNs for Improving 8-Methoxypsoralen Skin Delivery." Pharmaceutics 12, no. 10 (2020): 973. http://dx.doi.org/10.3390/pharmaceutics12100973.

Full text
Abstract:
Topical psoralens plus ultraviolet A radiation (PUVA) therapy consists in the topical application of 8-methoxypsoralen (8-MOP) followed by the skin irradiation with ultraviolet A radiation. The employment of classical 8-MOP vehicles in topical PUVA therapy is associated with poor skin deposition and weak skin permeability of psoralens, thus requiring frequent drug administration. The aim of the present work was to formulate solid lipid nanoparticles (SLNs) able to increase the skin permeation of 8-MOP. For this purpose, the penetration enhancer Transcutol® P (TRC) was added to the SLN formulation. SLNs were characterized with respect to size, polydispersity index, zeta potential, entrapment efficiency, morphology, stability, and biocompatibility. Finally, 8-MOP skin diffusion and distribution within the skin layers was investigated using Franz cells and newborn pig skin. Freshly prepared nanoparticles showed spherical shape, mean diameters ranging between 120 and 133 nm, a fairly narrow size distribution, highly negative ζ potential values, and high entrapment efficiency. Empty and loaded formulations were almost stable over 30 days. In vitro penetration and permeation studies demonstrated a greater 8-MOP accumulation in each skin layer after SLN TRC 2% and TRC 4% application than that after SLN TRC 0% application. Finally, the results of experiments on 3T3 fibroblasts showed that the incorporation of TRC into SLNs could enhance the cellular uptake of nanoparticles, but it did not increase their cytotoxicity.
APA, Harvard, Vancouver, ISO, and other styles
6

Zainuddin, Siti Aisyah, Abdul Latip Ab Hamid, Aqila Iman Rafandi, Mashani Mohamad, Khuriah Abdul Hamid, and Syed Haroon Khalid. "The Effects of Different Solubilizing Agents on the Transport and Pharmacokinetic Profiles of Indocmethacin: In vitro and in vivo Approach." Sains Malaysiana 53, no. 11 (2024): 3747–59. http://dx.doi.org/10.17576/jsm-2024-5311-17.

Full text
Abstract:
The poor water solubility of new chemical entities (NCEs) discovered in pharmaceutical screening programs hampers their development and limits effective treatment delivery. Solubilizing agents offer a direct approach to increase solubility and oral bioavailability. This study employed indomethacin as a model drug from Biopharmaceutical Classification System (BCS) class II. Solubilizing agents, including propylene glycol, Transcutol P, Labrasol, PEG 400, and Tween 80, were separately added at 10% (v/v) to 1 mg/5 mL for in vitro diffusion chamber and 10 mg/kg body weight for in vivo oral absorption studies of indomethacin. Drug concentrations were analysed using reversed-phase high-performance liquid chromatography (HPLC). In vitro, 10% (v/v) labrasol, PEG 400, and Tween 80 significantly (p<0.01) increased indomethacin permeability across the rat intestinal layer. However, Transcutol P and PG (propylene glycol 10%v/v) showed no discernible impact on in vitro permeability. In the in vivo oral absorption study, PG (propylene glycol 10%v/v) and Transcutol P significantly (p<0.05) enhanced indomethacin absorption, while 10% (v/v) labrasol, PEG 400, and Tween 80 did not show significant effects. No in vitro-in vivo correlation (IVIVC) was observed, likely due to the physicochemical properties of indomethacin and the complex physiological environment in the gastrointestinal (GI) tract. Further investigations are necessary to comprehensively understand the factors affecting indomethacin solubility and absorption, considering both the drug’s properties and the GI tract’s physiological conditions.
APA, Harvard, Vancouver, ISO, and other styles
7

Shin, Dong, Bo Chae, Yoon Goo, et al. "Improved Dissolution and Oral Bioavailability of Valsartan Using a Solidified Supersaturable Self-Microemulsifying Drug Delivery System Containing Gelucire® 44/14." Pharmaceutics 11, no. 2 (2019): 58. http://dx.doi.org/10.3390/pharmaceutics11020058.

Full text
Abstract:
To improve the dissolution and oral bioavailability of valsartan (VST), we previously formulated a supersaturable self-microemulsifying drug delivery system (SuSMED) composed of Capmul® MCM (oil), Tween® 80 (surfactant), Transcutol® P (cosurfactant), and Poloxamer 407 (precipitation inhibitor) but encountered a stability problem (Transcutol® P-induced weight loss in storage) after solidification. In the present study, replacing Transcutol® P with Gelucire® 44/14 resulted in a novel SuSMED formulation, wherein the total amount of surfactant/cosurfactant was less than that of the previous formulation. Solidified SuSMED (S-SuSMED) granules were prepared by blending VST-containing SuSMED with selective solid carriers, L-HPC and Florite® PS-10, wherein VST existed in an amorphous state. S-SuSMED tablets fabricated by direct compression with additional excipients were sufficiently stable in terms of drug content and impurity changes after 6 months of storage at accelerated conditions (40 ± 2 °C and 75 ± 5% relative humidity). Consequently, enhanced dissolution was obtained (pH 1.2, 2 h): 6-fold for S-SuSMED granules against raw VST; 2.3-fold for S-SuSMED tablets against Diovan® (reference tablet). S-SuSMED tablets increased oral bioavailability in rats (10 mg/kg VST dose): approximately 177–198% versus raw VST and Diovan®. Therefore, VST-loaded S-SuSMED formulations might be good candidates for practical development in the pharmaceutical industry.
APA, Harvard, Vancouver, ISO, and other styles
8

Censi, Roberta, Valentina Martena, Ela Hoti, Ledjan Malaj, and Piera Di Martino. "Permeation and skin retention of quercetin from microemulsions containing Transcutol®P." Drug Development and Industrial Pharmacy 38, no. 9 (2011): 1128–33. http://dx.doi.org/10.3109/03639045.2011.641564.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yudanti, Gendis Purno, Ilham Kuncahyo, and Endang Diyah Ikasari. "Optimization of Naringenin Self-Nano Emulsifying Drug Delivery System (SNEDDS) Formula with D-optimal Mixture Design Method." Journal of Pharmaceutical Sciences and Community 21, no. 1 (2024): 100–108. http://dx.doi.org/10.24071/jpsc.004319.

Full text
Abstract:
This study aimed to optimize and formulate the poorly water-soluble naringenin in the Self-Nano Emulsifying Drug Delivery System (SNEDDS) using D-optimal mixture design. D-optimal mixture design was used to optimize SNEDDS loading naringenin by selecting SNEDDS composition as an independent factor and SNEDDS characterization as a response. SNEDDS in the optimal formula were characterized, including transmittance, particle size, emulsification time, and drug loading. Triacetin, Tween 80, and transcutol p were respectively the selected oil, surfactant, and co-surfactant phases for their greatest ability to dissolve naringenin. The optimization results showed that the optimal formula was that using 10% triacetin, 70% of Tween 80, and 20% of transcutol p. SNEDDS loading naringenin produced nanoemulsion with 88.74±2.27 % of transmittance, 14.8 nm of particle size, 51.13 ± 4.53 mg/L of drug loading, and 18.58 ± 0.62 second of emulsification time. This study concludes that the D-optimal mixture design can be used to optimize and prepare the SNEDDS loading poorly-water soluble naringenin.
APA, Harvard, Vancouver, ISO, and other styles
10

Lee, Sang Gon, Jong Bu Kang, Sung Rae Kim, et al. "Enhanced topical delivery of tacrolimus by a carbomer hydrogel formulation with transcutol P." Drug Development and Industrial Pharmacy 42, no. 10 (2016): 1636–42. http://dx.doi.org/10.3109/03639045.2016.1160107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Transcutol P' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography